Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 17 of 17 entries
View as:

Long-Term Follow-up Protocol

Phase: N/A Priority: Normal
NCT ID: NCT04917887 Org: User:
Start: 05/25/21 End: 05/25/28 Due: 05/25/29

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Phase: N/A Priority: Normal
NCT ID: NCT04214002 Org: User:
Start: 01/31/20 End: 02/24/20 Due: 02/24/21

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Phase: N/A Priority: Normal
NCT ID: NCT04917874 Org: User:
Start: 05/25/21 End: 07/31/23 Due: 07/31/24

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

Phase: N/A Priority: Normal
NCT ID: NCT03536143 Org: User:
Start: 05/06/18 End: 11/01/19 Due: 11/01/20

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Phase: N/A Priority: Normal
NCT ID: NCT05735158 Org: User:
Start: 03/31/23 End: 04/30/24 Due: 04/30/25

Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Phase: N/A Priority: Normal
NCT ID: NCT04047732 Org: User:
Start: 08/27/19 End: 03/31/25 Due: 03/31/26

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT05504837 Org: User:
Start: 06/30/23 End: 07/31/25 Due: 07/31/26

A Study Assessing KB801 for the Treatment of Stage 2 or 3 Neurotrophic Keratitis

Phase: N/A Priority: Normal
NCT ID: NCT06999733 Org: User:
Start: 05/31/25 End: 10/31/26 Due: 10/31/27

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT05095246 Org: User:
Start: 03/08/22 End: 10/30/24 Due: 10/30/25

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Phase: N/A Priority: Normal
NCT ID: NCT04540900 Org: User:
Start: 10/07/20 End: 05/31/29 Due: 05/31/30

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT06049082 Org: User:
Start: 02/15/24 End: 05/31/26 Due: 05/31/27

A Study Assessing KB304 for the Treatment of Wrinkles in Women

Phase: N/A Priority: Normal
NCT ID: NCT06724900 Org: User:
Start: 11/20/24 End: 08/31/25 Due: 08/31/26

Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB

Phase: N/A Priority: Normal
NCT ID: NCT04491604 Org: User:
Start: 08/17/20 End: 01/14/22 Due: 01/14/23

A Study Assessing B-VEC Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa

Phase: N/A Priority: Normal
NCT ID: NCT07016750 Org: User:
Start: 06/30/25 End: 03/31/26 Due: 03/31/27

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05970497 Org: User:
Start: 10/31/23 End: 07/31/27 Due: 07/31/28

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Phase: N/A Priority: Normal
NCT ID: NCT06228326 Org: User:
Start: 04/17/24 End: 02/29/28 Due: 02/28/29

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Phase: N/A Priority: Normal
NCT ID: NCT06563414 Org: User:
Start: 08/02/24 End: 07/31/25 Due: 07/31/26